Uğur Şahin

Uğur Şahin is a Turkish-German physician, immunologist, and entrepreneur whose name became known across the world during the gravest health emergency of the twenty-first century. As the co-founder and chief executive of the German biotechnology company BioNTech, he helped lead the development, in partnership with Pfizer, of one of the first messenger RNA (mRNA) vaccines authorized against COVID-19. Yet to understand the significance of that achievement, one must look back across decades of quiet, patient research that long preceded the moment the world suddenly needed it.

He was born in 1965 in İskenderun, a port city in the Hatay Province of southern Turkey. When he was a young child, his family moved to Germany, part of the large wave of Turkish workers who came to the country in the post-war decades. His father found employment at a Ford automobile factory in Cologne. Şahin grew up in this immigrant working-class environment, a setting that did not obviously point toward a future at the frontier of medical science. Yet he showed an early fascination with how living things worked and with the questions of biology and disease. Books and curiosity, more than privilege, shaped his path.

He pursued medicine at the University of Cologne, earning his medical degree and then a doctorate. His early clinical work brought him into contact with cancer patients, and that experience marked him deeply. He saw how often the tools available to physicians fell short, how treatments that were meant to heal could also harm, and how patients with aggressive tumors had so few options. This was not an abstract scientific problem for him; it was a human one, faced at the bedside. The desire to give patients something better than the blunt instruments of conventional chemotherapy would become the organizing purpose of his career.

It was during these years that he met Özlem Türeci, herself a physician and immunologist, who would become both his closest scientific partner and his wife. Together they shared a conviction that the immune system itself could be taught to recognize and attack cancer, and that the emerging understanding of molecular biology could make this possible. The idea of harnessing the body’s own defenses against tumors—immunotherapy—was, at the time, far from the mainstream. Many in the field were skeptical. But the two of them committed themselves to it with a steadiness that would define their working lives.

Şahin built an academic career as a professor at the University of Mainz, where he studied immunology and the molecular biology of cancer. He and Türeci were not content, however, to confine their ideas to the laboratory and the journal article. They believed that scientific insight had to be translated into real therapies for real patients, and that this required building companies capable of carrying ideas through the long, expensive, and uncertain process of drug development. In 2001 they co-founded their first company, Ganymed Pharmaceuticals, which focused on antibody-based treatments for cancer. It was eventually sold, providing both validation of their approach and resources for what came next.

In 2008 Şahin and Türeci, together with the investor and entrepreneur Thomas Strüngmann and his brother, founded BioNTech in Mainz. The company’s central bet was on messenger RNA. mRNA is the molecule that cells use to carry the instructions from genes to the protein-making machinery of the cell. Şahin and his colleagues reasoned that if you could deliver synthetic mRNA into the body, you could instruct cells to produce a chosen protein—perhaps a fragment of a tumor, perhaps a piece of a virus—and thereby teach the immune system to recognize and respond to it. The vision was sweeping: individualized cancer vaccines, tailored to the specific mutations of each patient’s tumor.

For more than a decade, this was patient, unglamorous work. mRNA was notoriously unstable and difficult to deliver, and the field had to solve enormous technical problems before the molecule could become a practical medicine. BioNTech assembled expertise in mRNA design, in the lipid nanoparticles needed to carry it safely into cells, and in manufacturing. The company was, for most of its existence, a research-driven enterprise without a single approved product. It required deep conviction and considerable courage to keep building such an organization on the strength of a promise that had not yet been proven at scale.

Then, in early 2020, everything changed. Şahin read reports of a new coronavirus spreading in the Chinese city of Wuhan and recognized, with unusual speed, that the world stood at the edge of a pandemic. He understood that the mRNA platform BioNTech had spent years refining for cancer could, in principle, be redirected against an infectious disease far faster than traditional vaccines could be made. He launched an internal effort, which the company called “Project Lightspeed,” to design a vaccine against the virus. BioNTech partnered with the American pharmaceutical giant Pfizer to provide the scale of testing, manufacturing, and distribution that a global vaccine would demand.

What followed was one of the most remarkable feats in the history of medicine. In a matter of months—rather than the years vaccines normally require—the team designed candidate vaccines, tested them, and brought one through large clinical trials. In late 2020, the Pfizer-BioNTech vaccine became among the first COVID-19 vaccines authorized for emergency use, with reported efficacy that exceeded the hopes of most experts. Across the following years, hundreds of millions of doses were administered around the world. It is widely credited with saving an enormous number of lives and helping bring the acute phase of the pandemic under control.

Through all of this, Şahin remained known for a striking personal modesty. Stories circulated of his unassuming habits—of a man who cycled to work, who seemed indifferent to the trappings of wealth even as his company’s value soared, and who continued to describe himself first as a scientist and a physician. On the day the vaccine’s efficacy results were announced, he and Türeci reportedly marked the occasion quietly, with a cup of Turkish tea. His attention seemed always to return to the patients and to the science rather than to the acclaim.

He has been careful, too, to insist that the COVID-19 vaccine was not an end in itself but a demonstration of what mRNA technology could do. His enduring ambition remains the original one: to defeat cancer. BioNTech has continued to advance individualized cancer vaccines and other mRNA-based immunotherapies into clinical trials, pursuing the dream that first drew Şahin and Türeci together as young physicians. He has spoken of a future in which a patient’s tumor is sequenced, a bespoke vaccine is rapidly designed against its unique mutations, and the immune system is mobilized to destroy the cancer—a future that the pandemic, however terrible, may have brought significantly closer.

Şahin’s recognition has been considerable. He and Türeci have received numerous honors for their contributions to science and public health, and Germany has celebrated them as among its most distinguished researchers. Yet the deeper measure of his life is not in awards but in the convergence of long preparation and sudden need. For years he and his colleagues built a capability that the wider world neither fully understood nor urgently demanded. When the moment came, that quietly accumulated knowledge was ready, and it mattered to the entire human family.

There is a profound lesson in his story for anyone of any background. The son of a factory worker, an immigrant child in a foreign land, he reached the heights of his field not through privilege but through sustained dedication to a worthy purpose. He pursued a difficult idea for decades while many doubted it. He kept his focus on the suffering of patients rather than on personal gain. And when the hour of testing arrived, his patient labor became a gift to humanity. His life testifies that knowledge pursued with sincerity and perseverance can become a mercy to countless people one may never meet.